logo
Plus   Neg
Share
Email

JPMorgan Commits $30 Bln Over Next 5 Years To Advance Racial Equity - Quick Facts

JPMorgan Chase & Co. (c) announced Thursday an additional $30 billion long-term commitment to advance racial equity. The firm will harness its expertise in business, policy and philanthropy over the next five years to address key drivers of the racial wealth divide, reduce systemic racism against Black and Latinx people, and support employees.

Structural barriers in the U.S. have created profound racial inequalities that have been exacerbated by the COVID-19 pandemic. The existing racial wealth gap puts a strain on families' economic mobility and restricts the U.S. economy.

The firm will also provide $2 billion in philanthropic capital over the next five years to drive an inclusive economic recovery and support Black, Latinx and other underserved communities. This extends and increases the firm's current five-year $1.75 billion philanthropic commitment made in 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. tech giant Google is laying the groundwork for a fiber-optic network that will connect the first time through Saudi Arabia and Israel, opening a new global internet traffic corridor, the Wall Street Journal reported, citing people familiar with the plans. The link would be established as part of an optical-fiber cable line connecting Europe with India. U.S. retailers Best Buy Co. Inc., Abercrombie & Fitch Co., and Dollar Tree Inc. on Tuesday reported results for the third quarter that surpassed analysts' expectations. The upbeat results indicate that retailers have largely recovered from the impact of the coronavirus pandemic just as the holiday season approaches. The companies have also intensified their focused on digital sales. The U.S. Food and Drug Administration approved the first drug to treat primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder which causes recurrent kidney stones and loss of kidney function. Alnylam Pharmaceuticals' Oxlumo (lumasiran) in the form of injection lowers urinary oxalate levels in pediatric and adult patients.
Follow RTT